Civitas Therapeutics Extends CVT-301 Patent Protection Into 2032
Published: Nov 08, 2013
CHELSEA, Mass.--(BUSINESS WIRE)--Civitas Therapeutics, Inc., a biopharmaceutical company with a lead program in Parkinson’s disease that leverages the ARCUS® respiratory delivery platform, today announced the Unites States Patent and Trademark Office (USPTO) has issued US Patent 8,545,878 entitled “Capsules containing high doses of levodopa for pulmonary use.” This newly issued patent covers the pharmaceutical composition of CVT-301 and has an expiration date of November 16, 2032. US 8,545,878 is one of over 115 issued patents worldwide protecting CVT-301.
Help employers find you! Check out all the jobs and post your resume.